Carbamazepine Sensitivity HLA Associations
Also known as: Carbamazepine Sensitivity, HLA A*3101, HLA A*31:01, HLA A3101, HLA B*1502
Use
To avoid possible adverse reactions, this test has been recommended for patients who may be prescribed Carbamazepine and oxcarbazepine. Two HLA alleles are associated with adverse reactions to these drugs. The alleles are HLA B*15:02, which is more common in individuals of Asian descent, and HLA A*31:01, which is more common in individuals of European descent. This test evaluates the presence or absence of these alleles.
Special Instructions
Not provided.
Limitations
A negative test result does not rule out an adverse reaction to Carbamazepine and oxcarbazepine. Even with appropriate precautions, an occasional specimen may not be satisfactory for testing, in which case an additional specimen should be collected for retesting. This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
NGS
Biomarkers
HLA-A*31:01, HLA-B*15:02
Gene
LOINC Codes
- 13298-5 - HLA-A
- 57979-7 - HLA-B*15:02 Ql
- 49549-9 - Ref lab test method
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
7 mL whole blood
Minimum Volume
3 mL whole blood
Container
Lavender-top (EDTA) tube
Collection Instructions
For collection instructions or to obtain the buccal swab kit, please telephone 800-533-1037.
Storage Instructions
Maintain whole blood at room temperature or refrigerate.
Causes for Rejection
Insufficient volume of DNA
Other tests from different labs that may be relevant